{"entity":{"id":"nct05636618","kind":"trial","name":"Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors","aka":[],"tldr":"A phase 1/2 trial of [203Pb]VMT-α-NET in neuroendocrine tumours, pancreatic ductal adenocarcinoma and pheochromocytoma and paraganglioma, run by Perspective Therapeutics, now recruiting.","summary":"Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors is a phase 1/2 interventional study registered as NCT05636618 by Perspective Therapeutics, with 300 participants planned, started 2023-09-27 and due to reach its primary completion in 2029-11-26. Interventions recorded: [203Pb]VMT-α-NET and [212Pb]VMT-α-NET.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05636618","url":"https://clinicaltrials.gov/study/NCT05636618"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["neuroendocrine","pancreatic","pheochromocytoma-paraganglioma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["perspective-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05636618","phase":"1/2","setting":"A Phase I/IIa First-in-Human Study of [212Pb]VMT-α-NET Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Tumors","sponsor":"Perspective Therapeutics","participation":[{"nct":"NCT05636618","source":"https://clinicaltrials.gov/study/NCT05636618","fetchedAt":"2026-10-07T16:53:48.601Z","studySha256":"22136700dc16a1318df379b78936f72ad45583102efe2ad902e095271978c6db","overallStatus":"RECRUITING","lastUpdatePosted":"2026-05-14","leadSponsor":"Perspective Therapeutics","collaboratorCount":0,"minimumAge":"18 Years","maximumAge":"90 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":300,"enrolmentType":"ESTIMATED","siteCount":19,"recruitingSiteCount":19,"countries":["United States"]}],"started":"2023-09-27","startedType":"actual","enrolled":300,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05636618/","neighbours":{"cancer":[{"id":"neuroendocrine","kind":"cancer","name":"Neuroendocrine tumours","route":"/cancers/neuroendocrine/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"},{"id":"pheochromocytoma-paraganglioma","kind":"cancer","name":"Pheochromocytoma and paraganglioma (PPGL)","route":"/cancers/pheochromocytoma-paraganglioma/"}],"company":[{"id":"perspective-therapeutics","kind":"company","name":"Perspective Therapeutics","route":"/companies/perspective-therapeutics/"}]}}